Can-Fite Shares Rise After Enrollment Complete in Phase 3 Psoriasis Study
Can-Fite BioPharma ADR shares climbed in pre-market trade after the company confirmed it has finished enrolling patients for the interim analysis of its pivotal Phase 3 psoriasis trial. Interim results are now scheduled for release in Q4 2026 or Q1 2027. The development follows recent positive news around the firm's oncology program and continued a…